These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 19655821)

  • 1. Argatroban: a review of its use in the management of heparin-induced thrombocytopenia.
    Dhillon S
    Am J Cardiovasc Drugs; 2009; 9(4):261-82. PubMed ID: 19655821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
    Lewis BE; Wallis DE; Leya F; Hursting MJ; Kelton JG;
    Arch Intern Med; 2003 Aug 11-25; 163(15):1849-56. PubMed ID: 12912723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Argatroban in the management of heparin-induced thrombocytopenia.
    Babuin L; Pengo V
    Vasc Health Risk Manag; 2010 Sep; 6():813-9. PubMed ID: 20859550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia.
    Matthai WH
    Semin Thromb Hemost; 1999; 25 Suppl 1():57-60. PubMed ID: 10357153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
    Lewis BE; Wallis DE; Berkowitz SD; Matthai WH; Fareed J; Walenga JM; Bartholomew J; Sham R; Lerner RG; Zeigler ZR; Rustagi PK; Jang IK; Rifkin SD; Moran J; Hursting MJ; Kelton JG;
    Circulation; 2001 Apr; 103(14):1838-43. PubMed ID: 11294800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
    Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Lewis BE; Matthai WH; Cohen M; Moses JW; Hursting MJ; Leya F;
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):177-84. PubMed ID: 12357516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia.
    Kondo LM; Wittkowsky AK; Wiggins BS
    Ann Pharmacother; 2001 Apr; 35(4):440-51. PubMed ID: 11302409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.
    Boyce SW; Bandyk DF; Bartholomew JR; Frame JN; Rice L
    Am J Ther; 2011 Jan; 18(1):14-22. PubMed ID: 21079512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions.
    Escolar G; Bozzo J; Maragall S
    Drugs Today (Barc); 2006 Apr; 42(4):223-36. PubMed ID: 16703119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Argatroban in HIT type II and acute coronary syndrome.
    Lewis BE; Walenga JM
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 3():46-55. PubMed ID: 12811012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
    Hursting MJ; Soffer J
    Drug Saf; 2009; 32(3):203-18. PubMed ID: 19338378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
    Frame JN; Rice L; Bartholomew JR; Whelton A
    Clin Ther; 2010 Apr; 32(4):626-36. PubMed ID: 20435232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study.
    Young G; Boshkov LK; Sullivan JE; Raffini LJ; Cox DS; Boyle DA; Kallender H; Tarka EA; Soffer J; Hursting MJ
    Pediatr Blood Cancer; 2011 Jul; 56(7):1103-9. PubMed ID: 21488155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for heparin-induced thrombocytopenia.
    Greinacher A
    Am J Health Syst Pharm; 2003 Oct; 60 Suppl 5():S12-8. PubMed ID: 14593978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
    Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
    Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Lewis BE; Hursting MJ
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):57-68. PubMed ID: 17187457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.
    Lewis BE; Wallis DE; Hursting MJ; Levine RL; Leya F
    Chest; 2006 Jun; 129(6):1407-16. PubMed ID: 16778256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.